<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-24-44-b</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-24-6-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Seizure Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>UK Multicenter Randomized Trial of Hormonal Treatments Vs Vigabatrin for Infantile Spasms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>06</month>
<year>2010</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>01</month>
<year>2016</year>
</pub-date>
<volume>24</volume>
<issue>6</issue>
<fpage>44</fpage>
<lpage>45</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2010 The Author(s)</copyright-statement>
<copyright-year>2010</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1016/S0140-6736(04)17400-X" vol="364" page="1773">
<article-title>Vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>The UK Infantile Spasms Multicenter Study previously showed that seizure control after 14 days and development at 14 months are better following hormonal treatments (prednisolone or tetracosactide depot) than following vigabatrin.</p>
</abstract>
<kwd-group>
<kwd>Vineland Adaptive Behavior Scales</kwd>
<kwd>Hormonal Treatment</kwd>
<kwd>Vigabatrin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The UK Infantile Spasms Multicenter Study previously showed that seizure control after 14 days and development at 14 months are better following hormonal treatments (prednisolone or tetracosactide depot) than following vigabatrin [<xref ref-type="bibr" rid="CIT0001">1</xref>]. At 4-year follow-up, 9 of 107 enrolled infants had died and 77 were tested for level of development, using the Vineland Adaptive Behavior Scales (VABS), and for seizure control by questionnaire. The median VABS scores were 60 for 39 children allocated hormonal treatment and 50 for 38 allocated vigabatrin (p=0.91). For children with spasms with no identified etiology, VABS scores were 96 for 21 allocated hormonal treatment, and 63 for the 16 allocated vigabatrin (p=0.033). For all 77 infants, development and epilepsy outcomes were not significantly different between the two treatment groups at 4-year follow-up. In patients with no identifiable etiology, development was better at both 14 months and 4 years in those allocated hormonal treatment. [<xref ref-type="bibr" rid="CIT0002">2</xref>]</p>
<p>COMMENT. A review of the earlier report of the UKISS with a primary outcome of cessation of spasms on days 13 and 14 [<xref ref-type="bibr" rid="CIT0001">1</xref>] found the minimum doses used were vigabatrin 100 mg/kg/daily (n=52), oral prednisolone 40 mg day (n=30) or intramuscular tetracosactide depot 0.5 mg (40 IU) (n=25) on alternate days. Complete seizure control was obtained in 40 (73%) on hormonal treatments (prednisolone 21 (70%), tetracosactide 19 (76%)) and 28 (54%) on vigabatrin (p=0.043). Adverse events were reported in 30 (55%) of 55 infants on hormonal treatments and 28 (54%) of 52 on vigabatrin. Cessation of spasms occurred more often in infants on hormonal treatment than those given vigabatrin. Adverse events were common with both treatments. The subsequent studies show that hormonal treatment and vigabatrin are equally effective in control of infantile spasms with proven etiology, but for spasms with no identifiable cause, hormonal treatment is preferred.</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lux</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>RW</given-names>
</name>
<etal/>
</person-group>
<article-title>Vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial</article-title>
<source>Lancet</source>
<year>2004</year>
<month>Nov</month>
<volume>364</volume>
<issue>9447</issue>
<fpage>1773</fpage>
<lpage>1778</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(04)17400-X</pub-id>
<pub-id pub-id-type="pmid">15541450</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Lux</surname>
<given-names>AL</given-names>
</name>
<etal/>
</person-group>
<article-title>Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomized trial</article-title>
<source>Arch Dis Child</source>
<year>2010</year>
<month>May</month>
<volume>95</volume>
<issue>5</issue>
<fpage>382</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.1136/adc.2009.160606</pub-id>
<pub-id pub-id-type="pmid">20457702</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
